Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Oseltamivir products are in shortage in Canada (1 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
An antiviral used to treat and prevent influenza (the flu).
Products affected
1 / 6
In shortage since
Dec 31, 2025
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
NAT-OSELTAMIVIR
6MG · POWDER FOR SUSPENSION · NATCO PHARMA (CANADA) INC
DIN 02499894 · since Dec 31, 2025, no end estimate · Demand increase for the drug.
Resolved
JAMP OSELTAMIVIR
75MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02497425 · ended Apr 30, 2026 · Demand increase for the drug.
Resolved
TAMIFLU
6MG · POWDER FOR SUSPENSION · HOFFMANN-LA ROCHE LIMITED
DIN 02381842 · ended Mar 3, 2026 · Demand increase for the drug.
Resolved
TAMIFLU
75MG · CAPSULE · HOFFMANN-LA ROCHE LIMITED
DIN 02241472 · ended Feb 22, 2026 · Demand increase for the drug.
Resolved
JAMP OSELTAMIVIR
30MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02497409 · ended Feb 11, 2026 · Disruption of the manufacture of the drug.
Resolved
MINT-OSELTAMIVIR
75MG · CAPSULE · MINT PHARMACEUTICALS INC
DIN 02497476 · ended Oct 18, 2023 · Disruption of the manufacture of the drug.
Resolved
JAMP OSELTAMIVIR
75MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02497425 · ended Sep 19, 2023 · Increase in demand. Under allocation
Resolved
JAMP OSELTAMIVIR
75MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02497425 · ended Feb 1, 2023 · Demand increase for the drug.
Resolved
TAMIFLU
75MG · CAPSULE · HOFFMANN-LA ROCHE LIMITED
DIN 02241472 · ended Dec 14, 2022 · Demand increase for the drug.
Resolved
TAMIFLU
6MG · POWDER FOR SUSPENSION · HOFFMANN-LA ROCHE LIMITED
DIN 02381842 · ended Dec 9, 2022 · Demand increase for the drug.
Resolved
JAMP OSELTAMIVIR
75MG · CAPSULE · JAMP PHARMA CORPORATION
DIN 02497425 · ended Jul 19, 2022 · Disruption of the manufacture of the drug.
Resolved
TAMIFLU
6MG · POWDER FOR SUSPENSION · HOFFMANN-LA ROCHE LIMITED
DIN 02381842 · ended Apr 20, 2020 · Demand increase for the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Oseltamivir is currently affected by an active shortage report filed with Health Canada by NATCO PHARMA (CANADA) INC.
The reported cause is: demand increase for the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Oseltamivir is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AH).
Recent changes
No changes recorded yet.
Common questions
What is Oseltamivir used for?
An antiviral used to treat and prevent influenza (the flu).
When will Oseltamivir be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Oseltamivir in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.